MorphoSys (ETR:MOR) has been assigned a €145.00 ($168.60) target price by Berenberg Bank in a report issued on Wednesday, Borsen Zeitung reports. The brokerage presently has a “buy” rating on the stock. Berenberg Bank’s price objective would indicate a potential upside of 26.64% from the stock’s current price.
A number of other research firms also recently weighed in on MOR. Royal Bank of Canada set a €130.00 ($151.16) target price on MorphoSys and gave the stock a “buy” rating in a report on Tuesday, November 19th. Goldman Sachs Group set a €114.00 ($132.56) price target on MorphoSys and gave the company a “neutral” rating in a research report on Tuesday, November 19th. JPMorgan Chase & Co. set a €130.00 ($151.16) price objective on MorphoSys and gave the stock a “buy” rating in a report on Monday, November 18th. HSBC set a €81.00 ($94.19) price objective on MorphoSys and gave the company a “sell” rating in a research report on Friday, August 16th. Finally, Independent Research set a €110.00 ($127.91) price objective on MorphoSys and gave the company a “neutral” rating in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of €119.86 ($139.37).
MOR stock traded up €3.20 ($3.72) during trading on Wednesday, reaching €114.50 ($133.14). The company had a trading volume of 132,652 shares, compared to its average volume of 153,687. MorphoSys has a 52 week low of €79.70 ($92.67) and a 52 week high of €114.70 ($133.37). The company has a market cap of $3.62 billion and a P/E ratio of -37.64. The business has a 50 day moving average of €101.84 and a 200 day moving average of €98.76. The company has a debt-to-equity ratio of 9.78, a current ratio of 7.80 and a quick ratio of 7.63.
MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.
Featured Story: What is the strike price in options trading?
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.